JAK2-dependent MPN cells that are developed to be resistant to a JAK2 inhibitor are cross-resistant to other JAK2 inhibitors [60], suggesting MPN patients may be resilient to alternative JAK2 inhibitors following initial resistance. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.